Elafibranor · Iqirvo

Small molecule

Also known as GFT505

Approvedregulatory verdict

Evidence outlook

Approved: Primary Biliary Cholangitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CA
  • IQIRVO® (elafibranor) is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Marketing authorization with conditions for this indication is based on a randomized, placebo- controlled, phase III study that assessed alkaline phosphatase (ALP) and bilirubin as a composite biochemical surrogate endpoint (see 14 CLINICAL TRIALS).
Product first approved 2025Health Canada
EU
  • Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Product first approved 2024EMA
Featured evidence outside this drug's tracked markets:ELASCOPE (NCT07387549) · Primary Sclerosing Cholangitis · Phase 3 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Primary Biliary Cholangitis
NCT06730061 · Ipsen
2025-01-16 – 2032-04-08 · Primary Biliary Cholangitis
What this study did
Other / comorbidity
NCT07387549 · Ipsen
2026-05-14 – 2031-05-31 · Primary Sclerosing Cholangitis
What this study did
NCT02704403 · Genfit
2016-03 – 2020-10-28 · Nonalcoholic Steatohepatitis (NASH) With Fibrosis
What this study did
Phase 2 (9)
Primary Biliary Cholangitis
NCT03124108 · Genfit
2017-04-05 – 2018-10-31 · Primary Biliary Cholangitis (PBC)
What this study did
Other / comorbidity
NCT05627362 · Ipsen
2022-12-29 – 2031-09-23 · Primary Sclerosing Cholangitis
What this study did
NCT03953456 · Genfit
2019-08-16 – 2020-07-14 · Non-Alcoholic Fatty Liver
What this study did
NCT03883607 · Genfit
2019-06-25 – 2020-06-16 · Non Alcoholic Steatohepatitis
What this study did
NCT01694849 · Genfit
2012-09 – 2015-12 · Non-Alcoholic Steatohepatitis (NASH)
What this study did
NCT01271777 · Genfit
2011-01 – 2011-11 · Insulin Resistance, Abdominal Obesity
What this study did
NCT01261494 · Genfit
2010-12 – 2011-06 · Type II Diabetes Mellitus
What this study did
NCT01275469 · Genfit
2009-06 – 2010-01 · Impaired Glucose Tolerance, Abdominal Obesity
What this study did
NCT01271751 · Genfit
2009-01 – 2009-11 · Atherogenic Dyslipidaemia, Abdominal Obesity
What this study did
Phase 1 (9)
Other / comorbidity
NCT05543369 · Ipsen
2022-09-19 – 2023-03-10 · Healthy Volunteers
What this study did
NCT05564208 · Ipsen
2022-10-27 – 2023-01-14 · Healthy Participants
What this study did
NCT03985969 · Genfit
2019-09-23 – 2020-03-31 · Drug-drug Interaction
What this study did
NCT04171752 · Genfit
2019-11-22 – 2020-03-30 · Geriatrics, Healthy
What this study did
NCT03844555 · Genfit
2019-02-28 – 2020-03-21 · Renal Impairment, Renal Insufficiency, Kidney Diseases, Pharmacokinetics
What this study did
NCT03765671 · Genfit
2018-12-12 – 2019-06-14 · Hepatic Impairment, Liver Disease, Pharmacokinetics
What this study did
NCT02142127 · Genfit
2014-04 – 2015-04 · Healthy
What this study did
NCT02091310 · Genfit
2014-02 – 2015-02 · Healthy Volunteers
What this study did
NCT01474161 · Genfit
2011-11 – 2012-11 · Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases, Obese, Dyslipidemia
What this study did

Competitive landscape

This drug's own stage for Primary Biliary Cholangitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Elafibranor (Iqirvo): this drugApprovedSmall moleculePPAR-alpha/PPAR-deltaPartial signal
NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8)
Seladelpar (Livdelzi)ApprovedSmall moleculePPAR-deltaPartial signal
NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02).
NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results).
Saroglitazar (Lipaglyn)Phase 3Small moleculePPAR-alpha/PPAR-gammaPartial signal
NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29).
Pemafibrate (Parmodia)Phase 2Small moleculePPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
SetanaxibPhase 2Small moleculeNOX1/4not yet gradedNo reviewed efficacy summary in this indication
VolixibatPhase 2Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Iqirvo (Elafibranor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Primary Biliary CholangitisActive not recruiting
Est. primary completion 2026-12-17 · NCT06730061 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 3Primary Biliary CholangitisRecruiting
Est. primary completion 2029-05-31 · NCT06016842 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Phase 3Primary Sclerosing CholangitisRecruiting
Est. primary completion 2031-04-30 · NCT07387549 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Primary Sclerosing CholangitisActive not recruiting
Est. primary completion 2031-09-23 · NCT05627362 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 July 2026Topline resultELSPIRE phase IIIb topline
Ipsen · Source ↗